Sirolimus

Sirolimus Reactions 1704, p343 - 2 Jun 2018 Various toxicities: 8 case reports In a retrospective study, eight patients (five males and three females) [exact age at the time of reaction onset not stated] were described who developed who developed fever, vomiting, rash, diarrhoea, pain, oral mucositis/oral ulcer, increased alanine transaminase, increased aspartate aminotransferase or elevated total cholesterol during treatment with sirolimus [rapamycin; time to reaction onset not stated]. The patients had steroid-resistant vascular tumours with Kasabach–Merritt phenomenon. The patients started receiving oral sirolimus 0.8 mg/m two times daily at a intervals of 12 hours, at the age of ranging from 1 month to 20 months. The dose of sirolimus was adjusted to maintain the sirolimus level at 10-15 ng/mL. The duration of sirolimus treatment was 8-20 months. Subsequently, the patients developed grade 2 fever (two patients), grade 1/2 diarrhoea (two patients), grade 1 pain (one patient), grade 2 oral mucositis and ulcer (one patient), grade 1 vomiting and rash (one patient) and grade 1 increased alanine transaminase, grade 2 increased aspartate aminotransferase and grade 1 elevated total cholesterol (one patient). After symptomatic treatment, these side effects had resolved within two weeks. Author comment: "In the present study, analysed data are presented to support the use of sirolimus in clinical practise for the treatment of corticosteroid-resistant vascular tumours with KMP in eight infants." "Despite mild adverse reactions during the administration of sirolimus, the symptoms were generally alleviated after symptomatic treatment." Tan X, et al. Successful management of steroid-resistant vascular tumors associated with the Kasabach-Merritt phenomenon using sirolimus. Journal of Dermatology 45: 580-583, No. 5, 2018. Available from: URL: http:// doi.org/10.1111/1346-8138.14231 - China 803323550 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Sirolimus

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/sirolimus-90vOqtOSv6
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46986-y
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p343 - 2 Jun 2018 Various toxicities: 8 case reports In a retrospective study, eight patients (five males and three females) [exact age at the time of reaction onset not stated] were described who developed who developed fever, vomiting, rash, diarrhoea, pain, oral mucositis/oral ulcer, increased alanine transaminase, increased aspartate aminotransferase or elevated total cholesterol during treatment with sirolimus [rapamycin; time to reaction onset not stated]. The patients had steroid-resistant vascular tumours with Kasabach–Merritt phenomenon. The patients started receiving oral sirolimus 0.8 mg/m two times daily at a intervals of 12 hours, at the age of ranging from 1 month to 20 months. The dose of sirolimus was adjusted to maintain the sirolimus level at 10-15 ng/mL. The duration of sirolimus treatment was 8-20 months. Subsequently, the patients developed grade 2 fever (two patients), grade 1/2 diarrhoea (two patients), grade 1 pain (one patient), grade 2 oral mucositis and ulcer (one patient), grade 1 vomiting and rash (one patient) and grade 1 increased alanine transaminase, grade 2 increased aspartate aminotransferase and grade 1 elevated total cholesterol (one patient). After symptomatic treatment, these side effects had resolved within two weeks. Author comment: "In the present study, analysed data are presented to support the use of sirolimus in clinical practise for the treatment of corticosteroid-resistant vascular tumours with KMP in eight infants." "Despite mild adverse reactions during the administration of sirolimus, the symptoms were generally alleviated after symptomatic treatment." Tan X, et al. Successful management of steroid-resistant vascular tumors associated with the Kasabach-Merritt phenomenon using sirolimus. Journal of Dermatology 45: 580-583, No. 5, 2018. Available from: URL: http:// doi.org/10.1111/1346-8138.14231 - China 803323550 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off